- Home
- BRIA vs MDXH Comparison
BRIA vs MDXH Comparison
Compare BRIA & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRIA
- MDXH
- Stock Information
- Founded
- BRIA 2011
- MDXH 2003
- Country
- BRIA Singapore
- MDXH Belgium
- Employees
- BRIA N/A
- MDXH N/A
- Industry
- BRIA
- MDXH
- Sector
- BRIA
- MDXH
- Exchange
- BRIA NYSE
- MDXH Nasdaq
- Market Cap
- BRIA 73.0M
- MDXH 93.1M
- IPO Year
- BRIA 2024
- MDXH 2021
- Fundamental
- Price
- BRIA $2.57
- MDXH $1.50
- Analyst Decision
- BRIA
- MDXH Buy
- Analyst Count
- BRIA 0
- MDXH 1
- Target Price
- BRIA N/A
- MDXH $6.00
- AVG Volume (30 Days)
- BRIA 21.0K
- MDXH 119.9K
- Earning Date
- BRIA 03-18-2025
- MDXH 04-30-2025
- Dividend Yield
- BRIA N/A
- MDXH N/A
- EPS Growth
- BRIA N/A
- MDXH N/A
- EPS
- BRIA 92.24
- MDXH N/A
- Revenue
- BRIA $55,755,669.00
- MDXH $90,049,000.00
- Revenue This Year
- BRIA N/A
- MDXH $23.38
- Revenue Next Year
- BRIA N/A
- MDXH $16.84
- P/E Ratio
- BRIA $0.03
- MDXH N/A
- Revenue Growth
- BRIA 8.03
- MDXH 28.29
- 52 Week Low
- BRIA $2.30
- MDXH $1.35
- 52 Week High
- BRIA $4.38
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- BRIA N/A
- MDXH 35.65
- Support Level
- BRIA N/A
- MDXH $1.35
- Resistance Level
- BRIA N/A
- MDXH $1.65
- Average True Range (ATR)
- BRIA 0.00
- MDXH 0.13
- MACD
- BRIA 0.00
- MDXH -0.03
- Stochastic Oscillator
- BRIA 0.00
- MDXH 27.69
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.